357 related articles for article (PubMed ID: 26327576)
1. Molecular modelling of human 5-hydroxytryptamine receptor (5-HT2A) and virtual screening studies towards the identification of agonist and antagonist molecules.
Gandhimathi A; Sowdhamini R
J Biomol Struct Dyn; 2016 May; 34(5):952-70. PubMed ID: 26327576
[TBL] [Abstract][Full Text] [Related]
2. A novel identification approach for discovery of 5-HydroxyTriptamine 2A antagonists: combination of 2D/3D similarity screening, molecular docking and molecular dynamics.
Kumar R; Jade D; Gupta D
J Biomol Struct Dyn; 2019 Mar; 37(4):931-943. PubMed ID: 29468945
[TBL] [Abstract][Full Text] [Related]
3. Low Basicity as a Characteristic for Atypical Ligands of Serotonin Receptor 5-HT2.
Podlewska S; Bugno R; Lacivita E; Leopoldo M; Bojarski AJ; Handzlik J
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33494248
[TBL] [Abstract][Full Text] [Related]
4. Design of novel dopamine D
Zhang C; Li Q; Meng L; Ren Y
J Biomol Struct Dyn; 2020 Feb; 38(3):860-885. PubMed ID: 30916624
[TBL] [Abstract][Full Text] [Related]
5. Mechanism Exploration of Arylpiperazine Derivatives Targeting the 5-HT
Lin F; Li F; Wang C; Wang J; Yang Y; Yang L; Li Y
Molecules; 2017 Jun; 22(7):. PubMed ID: 28672848
[TBL] [Abstract][Full Text] [Related]
6. Identification of structural determinants of ligand selectivity in 5-HT₂ receptor subtypes on the basis of protein-ligand interactions.
Jang JW; Kim MS; Cho YS; Cho AE; Pae AN
J Mol Graph Model; 2012 Sep; 38():342-53. PubMed ID: 23085173
[TBL] [Abstract][Full Text] [Related]
7. Insights into the influence of 5-HT2c aminoacidic variants with the inhibitory action of serotonin inverse agonists and antagonists.
Galeazzi R; Massaccesi L; Piva F; Principato G; Laudadio E
J Mol Model; 2014 Mar; 20(3):2120. PubMed ID: 24562856
[TBL] [Abstract][Full Text] [Related]
8. Binding modes of chain arylpiperazines to 5-HT1a, 5-HT2a and 5-HT7 receptors.
Bielenica A; Kozioł AE; Struga M
Mini Rev Med Chem; 2013 Aug; 13(10):1516-39. PubMed ID: 24568298
[TBL] [Abstract][Full Text] [Related]
9. G protein- and agonist-bound serotonin 5-HT2A receptor model activated by steered molecular dynamics simulations.
Isberg V; Balle T; Sander T; Jørgensen FS; Gloriam DE
J Chem Inf Model; 2011 Feb; 51(2):315-25. PubMed ID: 21261291
[TBL] [Abstract][Full Text] [Related]
10. Predicted structures and dynamics for agonists and antagonists bound to serotonin 5-HT2B and 5-HT2C receptors.
Kim SK; Li Y; Abrol R; Heo J; Goddard WA
J Chem Inf Model; 2011 Feb; 51(2):420-33. PubMed ID: 21299232
[TBL] [Abstract][Full Text] [Related]
11. Molecular Determinants for Ligand Binding at Serotonin 5-HT
Córdova-Sintjago T; Sakhuja R; Kondabolu K; Canal CE; Booth RG
Int J Quantum Chem; 2012 Dec; 112(24):3807-3814. PubMed ID: 23913978
[TBL] [Abstract][Full Text] [Related]
12. Predictive in silico studies of human 5-hydroxytryptamine receptor subtype 2B (5-HT2B) and valvular heart disease.
Reid TE; Kumar K; Wang XS
Curr Top Med Chem; 2013; 13(11):1353-62. PubMed ID: 23675941
[TBL] [Abstract][Full Text] [Related]
13. Reliability of Docking-Based Virtual Screening for GPCR Ligands with Homology Modeled Structures: A Case Study of the Angiotensin II Type I Receptor.
Chen H; Fu W; Wang Z; Wang X; Lei T; Zhu F; Li D; Chang S; Xu L; Hou T
ACS Chem Neurosci; 2019 Jan; 10(1):677-689. PubMed ID: 30265513
[TBL] [Abstract][Full Text] [Related]
14. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.
Song J; Hanniford D; Doucette C; Graham E; Poole MF; Ting A; Sherf B; Harrington J; Brunden K; Stricker-Krongrad A
Assay Drug Dev Technol; 2005 Dec; 3(6):649-59. PubMed ID: 16438660
[TBL] [Abstract][Full Text] [Related]
15. AlphaFold2 structures guide prospective ligand discovery.
Lyu J; Kapolka N; Gumpper R; Alon A; Wang L; Jain MK; Barros-Álvarez X; Sakamoto K; Kim Y; DiBerto J; Kim K; Glenn IS; Tummino TA; Huang S; Irwin JJ; Tarkhanova OO; Moroz Y; Skiniotis G; Kruse AC; Shoichet BK; Roth BL
Science; 2024 Jun; 384(6702):eadn6354. PubMed ID: 38753765
[TBL] [Abstract][Full Text] [Related]
16. Template selection and refinement considerations for modelling aminergic GPCR-ligand complexes.
Urmi KF; Finch AM; Griffith R
J Mol Graph Model; 2017 Sep; 76():488-503. PubMed ID: 28818718
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore-based virtual screening, biological evaluation and binding mode analysis of a novel protease-activated receptor 2 antagonist.
Cho NC; Seo SH; Kim D; Shin JS; Ju J; Seong J; Seo SH; Lee I; Lee KT; Kim YK; No KT; Pae AN
J Comput Aided Mol Des; 2016 Aug; 30(8):625-37. PubMed ID: 27600555
[TBL] [Abstract][Full Text] [Related]
18. 5-HT
Peng Y; McCorvy JD; Harpsøe K; Lansu K; Yuan S; Popov P; Qu L; Pu M; Che T; Nikolajsen LF; Huang XP; Wu Y; Shen L; Bjørn-Yoshimoto WE; Ding K; Wacker D; Han GW; Cheng J; Katritch V; Jensen AA; Hanson MA; Zhao S; Gloriam DE; Roth BL; Stevens RC; Liu ZJ
Cell; 2018 Feb; 172(4):719-730.e14. PubMed ID: 29398112
[TBL] [Abstract][Full Text] [Related]
19. Identification of potential dual agonists of FXR and TGR5 using e-pharmacophore based virtual screening.
Sindhu T; Srinivasan P
Mol Biosyst; 2015 May; 11(5):1305-18. PubMed ID: 25787676
[TBL] [Abstract][Full Text] [Related]
20. Molecular modeling and docking study on dopamine D2-like and serotonin 5-HT2A receptors.
Duan X; Zhang M; Zhang X; Wang F; Lei M
J Mol Graph Model; 2015 Apr; 57():143-55. PubMed ID: 25728902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
